Display options
Cite
Ferrières J, Roubille F, Farnier M, et al. Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists. J Clin Med. 2021;10(24)doi: 10.3390/jcm10245938.
Ferrières, J., Roubille, F., Farnier, M., Jourdain, P., Angoulvant, D., Boccara, F., & Danchin, N. (2021). Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists. Journal of clinical medicine, 10(24), . https://doi.org/10.3390/jcm10245938
Ferrières, Jean, et al. "Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists." Journal of clinical medicine vol. 10,24 (2021). doi: https://doi.org/10.3390/jcm10245938
Ferrières J, Roubille F, Farnier M, Jourdain P, Angoulvant D, Boccara F, Danchin N. Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists. J Clin Med. 2021 Dec 17;10(24). doi: 10.3390/jcm10245938. PMID: 34945235.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2021 Dec 17;10(24). doi: 10.3390/jcm10245938.

Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists.

Journal of clinical medicine

Jean Ferrières, François Roubille, Michel Farnier, Patrick Jourdain, Denis Angoulvant, Franck Boccara, Nicolas Danchin

Affiliations

  1. Department of Cardiology, Toulouse Rangueil University Hospital, INSERM UMR 1295, Toulouse University School of Medicine, 31059 Toulouse, France.
  2. PhyMedExp, INSERM, CNRS, Cardiology Department, INI-CRT, CHU de Montpellier, Université de Montpellier, 34090 Montpellier, France.
  3. Equipe PEC2, EA 7460, Service de Cardiologie, CHU Dijon Bourgogne, Université de Bourgogne Franche-Comté, 21000 Dijon, France.
  4. CHU Bicêtre AP-HP, Inserm U999, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.
  5. Service de Cardiologie, Hôpital Trousseau, CHRU de Tours, EA4245 T2i Faculté de médecine et Université de Tours, 37000 Tours, France.
  6. GRC n°22, C2MV-Complications Cardiovasculaires et Métaboliques chez les Patients Vivant avec le Virus de L'immunodéficience Humaine, INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire de Cardio-métabolisme et Nutrition (ICAN), Hôpital Saint-Antoine Service de Cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, 75012 Paris, France.
  7. Département de Cardiologie, Hôpital Européen Georges Pompidou et Université de Paris, 75015 Paris, France.

PMID: 34945235 DOI: 10.3390/jcm10245938

Abstract

INTRODUCTION: Patients with established coronary artery disease (CAD) are at very high risk for cardiovascular events.

METHODS: The DAUSSET study is a national, multicenter, non-interventional study that included very high-risk CAD patients followed by French cardiologists. It aimed to describe real-life clinical practices for low-density lipoprotein (LDL) cholesterol control in the secondary prevention of CAD.

RESULTS: A total of 912 patients (mean age, 65.4 years; men, 76.1%; myocardial infarction, 69.4%; first episode, 80.1%) were analyzed. The LDL cholesterol goal was 70 mg/dL in most cases (84.9%). The LDL cholesterol goal <70 mg/dL was achieved in 41.7% of patients. Of the 894 (98.0%) patients who received lipid-lowering therapy, 81.2% had been treated more intensively after the cardiac event, 27.0% had been treated less intensively and 13.1% had been maintained. Participating cardiologists were very satisfied or satisfied with treatment response in 72.6% of patients. Moderate satisfaction or dissatisfaction with lipid-lowering therapy was related to not achieving objectives (100%), treatment inefficacy (53.7%), treatment intolerance (23.4%) and poor adherence (12.3%).

CONCLUSION: These real-world results show that lipid control in very high-risk patients remains insufficient. More than half of the patients did not achieve the LDL cholesterol goal. Prevention of cardiovascular events in these very high-risk patients could be further improved by better education and more intensive lipid-lowering therapy.

Keywords: coronary artery disease; dyslipidemia; guidelines adherence; hypercholesterolemia; myocardial infarction; secondary prevention

References

  1. Eur Heart J. 2016 Aug 1;37(29):2315-2381 - PubMed
  2. Eur J Prev Cardiol. 2018 Jul;25(10):1087-1094 - PubMed
  3. Lancet. 2005 Oct 8;366(9493):1267-78 - PubMed
  4. Eur J Prev Cardiol. 2016 Apr;23(6):636-48 - PubMed
  5. Eur Heart J. 2016 Oct 14;37(39):2999-3058 - PubMed
  6. Atherosclerosis. 2016 Dec;255:200-209 - PubMed
  7. Int J Cardiol. 2016 Nov 1;222:793-794 - PubMed
  8. Data Brief. 2016 Sep 29;9:616-620 - PubMed
  9. Eur Heart J. 2017 Aug 21;38(32):2459-2472 - PubMed
  10. Eur Heart J. 2020 Jan 1;41(1):111-188 - PubMed
  11. Curr Cardiol Rep. 2020 Jul 9;22(9):87 - PubMed
  12. Eur Heart J. 2020 Jun 21;41(24):2313-2330 - PubMed
  13. Eur J Prev Cardiol. 2018 Dec;25(18):1966-1976 - PubMed
  14. Arch Cardiovasc Dis. 2017 Mar;110(3):167-178 - PubMed
  15. Circulation. 2019 Jun 18;139(25):e1046-e1081 - PubMed

Publication Types

Grant support